| __timestamp | Incyte Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 347523000 | 46425000 |
| Thursday, January 1, 2015 | 479514000 | 81491000 |
| Friday, January 1, 2016 | 581861000 | 94291000 |
| Sunday, January 1, 2017 | 1326361000 | 121827000 |
| Monday, January 1, 2018 | 1197957000 | 160524000 |
| Tuesday, January 1, 2019 | 1154111000 | 200000000 |
| Wednesday, January 1, 2020 | 2215942000 | 275000000 |
| Friday, January 1, 2021 | 1458179000 | 328100000 |
| Saturday, January 1, 2022 | 1585936000 | 463800000 |
| Sunday, January 1, 2023 | 1627594000 | 565000000 |
| Monday, January 1, 2024 | 2606848000 | 731100000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Neurocrine Biosciences, Inc. and Incyte Corporation have been at the forefront of this transformative journey. From 2014 to 2023, Incyte Corporation has consistently outpaced its peer, with R&D expenses growing by approximately 368%, peaking in 2020. This surge underscores Incyte's commitment to pioneering therapies and expanding its pipeline.
Conversely, Neurocrine Biosciences, Inc. has demonstrated a steady, albeit more modest, increase in R&D spending, with a growth of around 1,117% over the same period. This reflects a strategic focus on targeted innovations and niche markets. As we look to the future, these trends highlight the dynamic strategies of these biotech leaders, each carving its path in the competitive landscape of medical advancements.
Analyzing R&D Budgets: Merck & Co., Inc. vs Neurocrine Biosciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: Pfizer Inc. vs Neurocrine Biosciences, Inc.
Analyzing R&D Budgets: Genmab A/S vs Incyte Corporation
Research and Development Investment: Neurocrine Biosciences, Inc. vs Exelixis, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and Grifols, S.A. Allocate Funds
R&D Insights: How Neurocrine Biosciences, Inc. and Alpine Immune Sciences, Inc. Allocate Funds
Research and Development Expenses Breakdown: Incyte Corporation vs Ascendis Pharma A/S
Incyte Corporation vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Veracyte, Inc.
Incyte Corporation or HUTCHMED (China) Limited: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Incyte Corporation and Viridian Therapeutics, Inc.